Progression-free survival (PFS) was significantly longer with olaparib in cohort A as well as in the combined (A plus B) cohort, and these results led to FDA approval of olaparib for mCRPC patients with a tumor alteration in any of 14 genes included in either cohort A or cohort B. Similarly, the TRITON2 trial investigated the PARP inhibitor rucaparib in mCRPC patients with a tumor alteration in BRCA1, BRCA2, or at least one of thirteen other putative DDR genes11,12. Here, BRCA2 is linked to neoplasm.